

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-17** | Period of Report: **2013-01-16**
SEC Accession No. [0001556247-13-000001](#)

([HTML Version](#) on [secdatabase.com](#))

ISSUER

REGENERON PHARMACEUTICALS INC

CIK: [872589](#) | IRS No.: [133444607](#) | State of Incorp.: **NY** | Fiscal Year End: **1231**
SIC: **2834** Pharmaceutical preparations

Business Address
*777 OLD SAW MILL RIVER
RD
TARRYTOWN NY 10591-6707
9143477000*

REPORTING OWNER

GOLDBERG MURRAY A

CIK: [1226435](#)
Type: **4** | Act: **34** | File No.: [000-19034](#) | Film No.: [13535185](#)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: 02/28/2011
Estimated average burden hours per response 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person GOLDBERG MURRAY A			2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) SVP Finance and Admin CFO Trea		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/16/2013			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
777 OLD SAW MILL RIVER ROAD			4. If Amendment, Date Original Filed(Month/Day/Year)					
(Street) TARRYTOWN, NY 10591								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/16/2013		S	(1)	2,051	D	\$170.57 (2)	64,419	D	
Common Stock	01/16/2013		S	(1)	1,200	D	\$171.11 (3)	63,219	D	
Common Stock	01/16/2013		S	(1)	2,200	D	\$172.77 (4)	61,019	D	
Common Stock	01/16/2013		S	(1)	2,227	D	\$173.37 (5)	58,792	D	
Common Stock	01/16/2013		S	(1)	200	D	\$174.56 (6)	58,592	D	
Common Stock								5,560	I	By 401(k) Plan
Common Stock								750	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	--	--------------------------------------	--	--------------------------------	--	--	---	--	--	--	--

				(Instr. 3, 4, and 5)						
Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
2. Represents volume-weighted average price of sales of 2,051 shares of Company stock on January 16, 2013 at prices ranging from \$170.31 to \$170.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 16, 2013 at each separate price.
3. Represents volume-weighted average price of sales of 1,200 shares of Company stock on January 16, 2013 at prices ranging from \$171.00 to \$171.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 16, 2013 at each separate price.
4. Represents volume-weighted average price of sales of 2,200 shares of Company stock on January 16, 2013 at prices ranging from \$172.03 to \$172.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 16, 2013 at each separate price.
5. Represents volume-weighted average price of sales of 2,227 shares of Company stock on January 16, 2013 at prices ranging from \$173.01 to \$173.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 16, 2013 at each separate price.
6. Represents volume-weighted average price of sales of 200 shares of Company stock on January 16, 2013 at prices ranging from \$174.27 to \$174.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 16, 2013 at each separate price.

Signatures

/s/**Murray A. Goldberg

** Signature of Reporting Person

01/17/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.